PanCareLIFE in article on cancer survivorship

PanCareLIFE and the PanCare network were highlighted in a recent article in Cancer World, ‘Rerouted, not derailed: resuming a young life after cancer’.

PanCareLIFE Coordinator Dr. Peter Kaatsch commented:

There is no place for competition in paediatric oncology. We all work in a team. The PanCare network summarises this spirit: cooperation.

Dr. Gabriele Calaminus, leader of the health-related quality of life research in PanCareLIFE, noted:

The increase in the childhood cancer cure rate has been dramatic over the past twenty years. We now have more children who survive than who die. But what happens to them when they walk out the doors of the ‘Kinderonko’, when they’re finished with their treatments? The price of their recovery remains very high.

Through research into the late effects of cancer treatment PanCareLIFE aims to ensure that survivors of cancer diagnosed before age 25 enjoy the same quality of life and opportunities as their peers who have not had cancer.

CW article

PanCareLIFE in Vox Pediatriae

In September 2015, PanCareLIFE researcher Dr. Jarmila Kruseová from FN Motol in Prague has published an article ‘Late Effects after Treatment of Solid Tumours in Children in Vox Pediatriae, a Czech magazine for pediatricians.

Vox pediatr

PanCareLIFE in the Boyne Research Institute Newsletter

Read more about PanCareLIFE, PanCare and PanCareSurFup in the recent newsletter from the Boyne Research Institute.

Screen Shot 2015-09-24 at 11.53.02

PanCare Paper on Survivorship after Childhood Cancer

The PanCare network has been described in a paper published in the European Journal of Cancer. The PanCareLIFE project is presented alongside our sister project, PanCareSurFup. Both projects have arisen from work of the PanCare network and its collaborators.

PanCareLIFE and PanCareSurFup partners publish ‘Childhood cancer survivor cohorts in Europe’

A new publication from PanCareLIFE and PanCareSurFup partners about ‘Childhood cancer survivor cohorts in Europe’ has been published in Acta Oncologica.

The paper presents an overview of the current large, national and pan-European studies of late effects after childhood cancer, in particular the EU-funded collaborative research projects PanCareSurFup and PanCareLIFE. The large cohort studies described in the paper aim to provide every European childhood cancer survivor with better care and better long-term health so that they reach their full potential and enjoy the same quality of life and opportunities as their peers, as much as is possible.

Read More: http://informahealthcare.com/doi/abs/10.3109/0284186X.2015.1008648

 

Dynamics of fertility impairment in childhood brain tumour survivors.

This article can be accessed through this link.

PURPOSE:

Fertility impairment and recovery after chemo- and radiotherapy have been reported in both male and female childhood cancer survivors, but little is known about the dynamics. Our aim, therefore, was to describe the development of fertility impairment and possible recovery in childhood brain tumour survivors.

METHODS:

In this longitudinal study, we included 144 survivors, who were treated in two German paediatric oncology centres between 2000 and 2005. Fertility parameters were retrieved from medical records up to 12 years after diagnosis.

RESULTS:

Participants with age ≥13 years and formerly cranial irradiation ≥30 Gray (n = 23), including 83 % (n = 19) with craniospinal irradiation ≥30 Gray, had a higher median FSH concentration compared to 29 patients without chemoradiotherapy: 8.3 IU/l (IQR 6.5-11.2) versus 4.1 IU/l (IQR 3.2-5.1) 2 years after initial treatment; 8.9 IU/l (IQR 8.5-10.8) versus 4.2 IU/l (IQR 2.4-6.7) after 8 years; and 7.1 IU/l (IQR 6.7-7.7) versus 3.5 IU/l (IQR 2.8-4.2) after 10 years. Altogether, 11/65 women reported the occurrence of amenorrhoea 6.0 years (range 1-10) after diagnosis. Five of these women later developed a regular menstrual cycle without hormone replacement therapy. Patients’ chance of recovery from fertility impairment was increased with time since diagnosis (p = 0.074).

CONCLUSION:

Signs of fertility impairment such as amenorrhoea and elevated FSH levels were observed at variable time points between 1 and 12 years after chemoradiotherapy. Decreasing FSH levels were observed 1-7 years after elevation and were interpreted either as an atrophy of the pituitary gland or as recovery from fertility impairment.

Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study.

This article can be accessed through this link.

PURPOSE:

Fertility impairment and recovery after haematopoietic stem cell transplantation (HSCT) have been reported in both sexes, but little is known about how they develop over time. Our aim was to describe the dynamics of fertility impairment and recovery after HSCT.

METHODS:

We retrieved treatment and fertility data for up to 12 years of 361 paediatric patients with malignant and non-malignant diseases from seven European centres. The patients had been treated with allogeneic HSCT between 2000 and 2005.

RESULTS:

Development of fertility impairment was observed in males (123/217, 56 %) after a median time of 2.6 years (range 0.1-11.4) and in females (82/144, 57 %) after 2.3 years (range 0.1-12.0) after HSCT. Different busulfan dosages had only a slight impact on the onset of fertility impairment (busulfan ≥16 mg/kg with a median time to fertility impairment of 2.9 vs. 3.9 years after busulfan <14 mg/kg). Recovery from fertility impairment was observed in 17 participants after a median time of 4.1 years (range 1-10.6) in females (10/144, 7 %) and 2.0 years (range 1-6.3) in males (7/217, 3 %) after fertility impairment first appeared.

CONCLUSIONS:

In the light of the dynamics of fertility impairment and recovery in the HSCT patients reviewed, these patients should be counselled comprehensively regarding fertility preservation measures.

Related Publication: Understanding platinum-induced ototoxicity

Understanding Platinum-Induced Ototocity

Langer Tam Zehnhoff-Dinnesen ARadtke SMeitert JZolk O.

Trends Pharmacol Sci. 2013 Aug;34(8):458-69. doi: 10.1016/j.tips.2013.05.006. Epub 2013 Jun 13.

Related Publication: Impact of chemotherapy and radiotherapy in childhood on fertility in adulthood

Reinmuth S, Hohmann C, Rendtorff R, Balcerek M, Holzhausen S, Müller A, Henze G, Keil T, Borgmann-Staudt A.

J Cancer Res Clin Oncol. 2013 Dec;139(12):2071-8. doi: 10.1007/s00432-013-1527-9. Epub 2013 Oct 2.